AKTIENANLEIHE - DERMAPHARM HOLDING Stock

Certificat

DE000DQ0SWX4

Real-time Boerse Frankfurt Warrants 02:34:17 2024-05-29 EDT
96.2 EUR -0.08% Intraday chart for AKTIENANLEIHE - DERMAPHARM HOLDING
Current month+11.67%
1 month+10.25%
Date Price Change
24-05-29 96.2 -0.08%
24-05-28 96.28 -0.24%
24-05-27 96.51 +0.16%
24-05-24 96.36 -0.78%
24-05-23 97.12 -0.15%

Real-time Boerse Frankfurt Warrants

Last update May 29, 2024 at 02:34 am

More quotes

Static data

Product typeBonos de Acciones
Buy / SellCALL
Underlying DERMAPHARM HOLDING SE
Issuer DZ BANK
WKN DQ0SWX
ISINDE000DQ0SWX4
Date issued 2024-02-20
Strike 40
Maturity 2025-03-21 (297 Days)
Parity 0.04 : 1
Emission price 100
Emission volume N/A
Settlement Ambos
Currency EUR

Technical Indicators

Highest since issue 100.9
Lowest since issue 86.22
Spread 5.4
Spread %0.56%

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Sector
-
More about the company

Ratings for Dermapharm Holding SE

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Dermapharm Holding SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.9 EUR
Average target price
56.9 EUR
Spread / Average Target
+54.20%
Consensus